Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Operating Income: 2020-2025

Historic Operating Income for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to -$18.5 million.

  • Foghorn Therapeutics' Operating Income rose 22.43% to -$18.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.5 million, marking a year-over-year increase of 16.92%. This contributed to the annual value of -$102.7 million for FY2024, which is 4.84% up from last year.
  • Latest data reveals that Foghorn Therapeutics reported Operating Income of -$18.5 million as of Q3 2025, which was up 12.31% from -$21.1 million recorded in Q2 2025.
  • Foghorn Therapeutics' Operating Income's 5-year high stood at -$17.1 million during Q3 2023, with a 5-year trough of -$33.3 million in Q1 2023.
  • Moreover, its 3-year median value for Operating Income was -$24.0 million (2024), whereas its average is -$24.8 million.
  • Its Operating Income has fluctuated over the past 5 years, first crashed by 68.54% in 2021, then skyrocketed by 39.56% in 2023.
  • Quarterly analysis of 5 years shows Foghorn Therapeutics' Operating Income stood at -$28.1 million in 2021, then fell by 13.55% to -$31.9 million in 2022, then rose by 20.16% to -$25.5 million in 2023, then grew by 5.71% to -$24.0 million in 2024, then grew by 22.43% to -$18.5 million in 2025.
  • Its last three reported values are -$18.5 million in Q3 2025, -$21.1 million for Q2 2025, and -$22.9 million during Q1 2025.